| Objective : to explore the clinical effect of subcutaneous immunotherapy with standardized dust mite allergen vaccine on dust mite allergic rhinitis.Methods:collected the allergic rhinitis patients who were only allergic to dust mites and had received subcutaneous immunotherapy or symptomatic treatment for over 1 year in our hospital in recent 3 years,including 39 patients who received subcutaneous immunotherapy and 33 patients who received symptomatic treatment.To compare and evaluate the efficacy of subcutaneous immunotherapy and symptomatic treatment from five aspects: nasal symptom score,visual analogue score(VAS),drug score,whether allergic rhinitis develops into asthma and whether there are new allergens.Results:After 1 year of treatment,the scores of nasal symptoms,visual analogue scores and drug scores of the subcutaneous immunotherapy group were significantly reduced compared with that of 1 year ago,the difference was statistically significant(P<0.05).There was also a significant decrease compared with symptomatic treatment group,the difference was statistically significant(P<0.05).1/39(2.6%)of the patients in the subcutaneous immunotherapy group and 3/33(9.1%)of the patients in the symptomatic treatment group developed into asthma,the difference was not statistically significant(P > 0.05).2/39(5.1%)of the patients in the subcutaneous immunotherapy group and 5/33(15.2%)of the patients in the symptomatic treatment group showed new allergens,the difference was not statistically significant(P > 0.05).Conclusions:1.Subcutaneous immunotherapy can alleviate the nasal symptoms of the Allergic rhinitis patients;2.Subcutaneous immunotherapy can reduce the application of drugs used to control nasal symptoms in allergic rhinitis patients.3.However,there was no statistically significant difference between the SCIT group and the ST group in the prevention of AR progression to bronchial asthma and the emergence of new allergens. |
PDF Full Text Request